The Safety and Efficacy of Umbilical Cord Blood Mononuclear Cells in Patients With Secondary Poor Graft Function After Hematopoietic Stem Cell Transplantation

Inclusion criteria

• Age≥18 years old; gender is not limited.
• Meet the diagnostic criteria for secondary poor graft function: After 28 days of transplantation, patients who had achieved hematopoietic reestablishment (ANC ≥ 0.5×10^9/L for 3 consecutive days without G-CSF application, PLT ≥ 20×10^9/L for 7 consecutive days without platelet infusion, Hb ≥ 80g/L for 2 consecutive weeks without red blood cell infusion) again developed two or three line cytopenia lasting more than 2 weeks. Bone marrow examination revealed low myelodysplasia, remission of primary disease, complete donor chimeric cells, and no severe graft-versus-host disease (GVHD) or disease recurrence.
• Eastern Cooperative Oncology Group (ECOG) physical status score ≤ 2 points.
• Subjects sign informed consent.

Exclusion criteria

• Serious infection not controlled.
• Active bleeding.
• Patients with cardiac insufficiency (ejection fraction<50%), or suffering from serious heart disease, including myocardial infarction, cardiac insufficiency, etc.
• Patients with hepatic and renal insufficiency (total bilirubin>35µmol/L, ALT and AST>2 times of the upper limit of normal; serum creatinine>130µmol/L).
• Pregnant or lactating women.
• Concurrent malignant tumors of other organs.
• Failure to understand or follow the research protocol.
• Patients participating in other clinical investigations.
• Other conditions that the investigators consider inappropriate to participate in the study.